Abstract
Transport via the intestinal lymphatic system has been shown to contribute to the absorption of a number of highly lipophilic xenobiotics (Yeung and von Saigent, 1972; Noguchi et al., 1985; Fukui et al., 1989; Ichihashi et al., 1991a). Although intestinal lymphatic drug transport leads directly to an increase in oral bioavailability, it also confers other potential advantages such as avoidance of hepatic first-pass metabolism, direct targeting to the associated lymphoid tissue, and indirect targeting to specific sites such as those associated with low-density lipoprotein receptors and lymphocytes (Bijsterbosch and van Berkel, 1990; Charman and Stella, 1991).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
